Mood disturbance remains common in people living with HIV despite successful viral suppression on therapy. The authors investigated whether historical markers of untreated immunosuppression — specifically delays in antiretroviral therapy (ART) initiation and low nadir CD4 counts — have long-term associations with mood symptoms in adults with chronic HIV disease. The study also evaluated demographic and other HIV clinical factors to clarify which elements relate to current mood status.
This cross-sectional study enrolled 109 people with HIV (PWH) and 42 demographically matched people without HIV (PWoH). Participants were middle-aged (mean age 55.6 ± 6.8 years) with long HIV disease duration among PWH (mean 24.6 ± 9.3 years). The sample was predominantly African American (62.9%) and included 27.2% female participants; mean education across participants was 14.3 ± 2.9 years.
Mood symptoms were measured with two standard instruments: the Beck Depression Inventory-II (BDI-II) and the Profile of Mood States (POMS), including POMS subscales. Neurocognitive function was assessed using a comprehensive neuropsychological battery to compare cognitive performance between groups.
Clinical variables collected for PWH included time to ART initiation (delay from diagnosis to starting therapy), nadir CD4 count, current plasma CD4+ cell count, plasma HIV RNA detectability, and duration of HIV disease. The report states that ethical approval was obtained from the Institutional Review Board of Georgetown University Medical Center and that deidentified data are available on reasonable request.
The study found that, although neurocognitive performance was largely comparable between PWH and PWoH, mood outcomes differed. People with HIV had significantly higher total BDI-II scores (p < .001) and higher total POMS scores (p = .002) than the control group. PWH also scored worse on all POMS subscales with the exception of Vigor, where no significant difference was observed (p = .724). All reported POMS subscale differences (other than Vigor) reached statistical significance at p < .007 according to the source.
Within the PWH group, longer delays in initiating ART and lower nadir CD4 counts were associated with worse mood symptoms on the BDI-II and POMS measures. Lower educational attainment was also associated with worse mood. By contrast, current plasma CD4+ cell count, detectable plasma viral load, and total HIV disease duration were not associated with either BDI-II or POMS scores in this cohort.
The authors frame these findings as evidence of a long-term legacy effect: historical periods of untreated HIV and severe immunosuppression (reflected by delayed ART and low nadir CD4) appear to relate to persistent mood disturbance even when patients are on ART.
The report concludes that mood disturbance remains highly prevalent among PWH on ART, and that historical delays in ART initiation and low nadir CD4 counts have measurable, long-term associations with current mood symptoms. These observations are used to support the clinical importance of initiating ART early to reduce not only immunologic and virologic complications but also potential long-term neuropsychiatric consequences.
Clinicians should be aware that among people with chronic HIV, mood symptoms may reflect earlier periods of delayed treatment or profound immunosuppression rather than current viral or CD4 status. Attention to mood assessment and management remains important in long-term HIV care, particularly for patients with known prior delays in ART or documented low nadir CD4 counts.
This work is presented as a medRxiv preprint and has not undergone peer review; the authors note the standard caveat that findings should not directly guide clinical practice until validated. The article reports IRB approval from Georgetown University Medical Center. Specific details about statistical models, effect sizes, and covariate adjustments were not reproduced in the summarized source beyond the reported group comparisons and associations; those details are available in the full preprint and supplementary material referenced in the source. Deidentified data are available from the authors upon reasonable request. Funding from the National Institutes of Health is declared in the source.
In this sample of middle-aged adults with long-standing HIV, delayed initiation of antiretroviral therapy and lower nadir CD4 count were associated with worse mood symptoms measured by BDI-II and POMS, independent of current CD4 count or detectable viral load. The findings underscore the potential long-term neuropsychiatric consequences of delayed ART and support early initiation of therapy, while noting the preprint status and the need for peer review and further study.